Professor Tian Yantao's list commented "The front -line immunotherapy of gastric cancer achieves a comprehensive breakthrough"

On July 1, the "Top Ten Progress in the Cancer Field of the Public Public Most Incurities in 2021" was launched in "I do practical practice activities for the masses · Healthy Chinese Oncology Prevention and Control (2022-2023) and" Tumor's Things "column launched The launching ceremony was officially released.

(The above comments are from the chairman of the Popular Science Professional Committee of the China Anti -Cancer Association of the China Anti -Cancer Association and the director of the pancreas and gastric surgery of the Cancer Hospital of the Chinese Academy of Medical Sciences)

Most of the gastric cancer patients in my country are in the middle and late stages. While promoting early diagnosis and early treatment, a large number of patients with gastric cancer in the middle and advanced stages urgently need to treat us to improve the treatment effect of such patients. As a global multi-centered and random control study, Check-Mate-649 is the first phase III clinical study to obtain positive results in gastric cancer immunotherapy.

This study realizes OS and PES dual benefits in the overall population, and has good safety. It has brought new hope to the treatment of advanced gastric cancer, and it has also become an important basis for rewriting clinical guidelines! As the country who participates in the most patients, the national drug supervisor is The bureau quickly approved the indications of the first -line treatment of the drug at the first -line gastric cancer, reflecting the national level of the emphasis on improving the effect of gastric cancer treatment in my country, and also greatly met the urgent needs of patients at present!

Checkmate-649 is a new session of gastric cancer treatment. The treatment of gastric cancer is moving towards a new era. I believe that more patients will benefit in the future!

- END -